AMLX Stock Summary and Trading Ideas (Amylyx Pharmaceuticals | NASDAQ:AMLX)

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Amylyx Pharmaceuticals trades on the NASDAQ stock market under the symbol AMLX.

As of August 21, 2026, AMLX stock price declined to $38.66 with 3,851,959 million shares trading.

AMLX has a beta of 0.46, meaning it tends to be less sensitive to market movements. AMLX has a correlation of 0.00 to the broad based SPY ETF.

AMLX has a market cap of $4.29 billion. This is considered a Mid Cap stock.

In the last 3 years, AMLX traded as high as $41.14 and as low as $1.58.

The top ETF exchange traded funds that AMLX belongs to (by Net Assets): IWM, VTI, IWO, IBB, XPH.

AMLX has outperformed the market in the last year with a price return of +358.6% while the SPY ETF gained +21.7%. AMLX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +177.5% and +69.4%, respectively, while the SPY returned +3.4% and -1.0%, respectively.

AMLX support price is $37.72 and resistance is $41.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMLX shares will trade within this expected range on the day.